Publicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (20)

2023

  1. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  2. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

    Journal of Medical Virology, Vol. 95, Núm. 12

2021

  1. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712

  2. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. Sample pooling for SARS-CoV-2 RT-PCR screening

    Clinical Microbiology and Infection, Vol. 26, Núm. 12, pp. 1687.e1-1687.e5

  2. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300

2019

  1. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

2017

  1. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study)

    Journal of Viral Hepatitis, Vol. 24, Núm. 9, pp. 725-732

2016

  1. Using NS5B sequencing for hepatitis C virus genotyping reveals discordances with commercial platforms

    PLoS ONE, Vol. 11, Núm. 4

2015

  1. Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

2013

  1. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 9, pp. 1994-2002

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2010

  1. Evaluación crítica de los nuevos métodos comerciales para la determinación de la carga viral del VIH-1 y del VHC

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. SUPPL. 1, pp. 62-67

2007

  1. Infection by the type 2 human immunodeficiency virus and types 1 and 2 human lymphotropic virus in Spain

    Medicina Clinica

2005

  1. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients

    Journal of Medical Virology, Vol. 77, Núm. 1, pp. 23-28

  2. Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain

    Journal of Clinical Virology, Vol. 33, Núm. 1, pp. 65-70

2004

  1. HIV-2 and HTLV-I/II infections in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 22, Núm. 3, pp. 177-182

2000

  1. Prevalence of HTLV infection in pregnant women in Spain

    Sexually Transmitted Infections, Vol. 76, Núm. 5, pp. 366-370